MULTIPLE MYELOMA (MM)

This early-stage study is testing whether a new drug called cemsidomide, when combined with another drug (elranatamab), is safe for people with multiple myeloma that has returned or no longer responds to standard treatments. About 60 participants will receive different doses of c…

This study tests a combination of two drugs (CM336 and isatuximab) in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function and control the myeloma. Participants receive three cycles…

This study tests two different drug combinations (teclistamab plus daratumumab or talquetamab plus daratumumab) given for a fixed time in 150 frail patients newly diagnosed with multiple myeloma. The goal is to see how long the cancer stays under control and how well patients tol…

This study tests whether a combination of two drugs (elranatamab and daratumumab) can work as well as or better than a stem cell transplant followed by maintenance therapy for people newly diagnosed with multiple myeloma. About 100 participants will be randomly assigned to one of…

This study tests whether raising levels of beta-hydroxybutyrate (BHB), a natural molecule produced during fasting or a low-carb diet, can safely improve immunotherapy for multiple myeloma. About 45 patients receiving CAR-T cells or bispecific antibodies will be randomly assigned …

This early-phase study tests a new injection called OriV508 in 40 adults with multiple myeloma or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at how well it works agai…

This study tests whether adding an experimental drug called SCTC21C to standard chemotherapy (VRd) can help people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 292 participants who are not eligible for a stem cell transplant will be …

This study tests whether a 6-month, personalized exercise program (mixing home and hospital sessions) can improve quality of life for people with multiple myeloma. About 86 patients, aged 60 and older, who are not eligible for transplant will be randomly assigned to either receiv…

This study looks at 60 people with early blood conditions (MGUS or SMM) that can sometimes turn into multiple myeloma, a type of blood cancer. Researchers will use advanced genetic and immune testing to find clues that predict progression. The goal is to better identify high-risk…

This study observes 60 adults with multiple myeloma who are about to receive CAR-T cell therapy. Researchers will measure a specific immune marker (TCF-1) in patients' blood before treatment and track how long the modified CAR-T cells survive afterward. The goal is to find clues …